Ekso Bionics Holdings Inc (NASDAQ:EKSO)’s share price was down 11.5% during mid-day trading on Tuesday . The stock traded as low as $2.15 and last traded at $2.15. Approximately 805,220 shares traded hands during trading, an increase of 31% from the average daily volume of 612,592 shares. The stock had previously closed at $2.43.

A number of equities research analysts have weighed in on the company. ValuEngine raised Ekso Bionics from a “hold” rating to a “buy” rating in a report on Thursday, July 12th. Zacks Investment Research raised Ekso Bionics from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a report on Thursday, July 19th.

The firm has a market capitalization of $130.79 million, a P/E ratio of -2.53 and a beta of -0.36. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.17 and a quick ratio of 1.92.

Ekso Bionics (NASDAQ:EKSO) last announced its earnings results on Tuesday, August 7th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The business had revenue of $2.97 million during the quarter, compared to analyst estimates of $3.03 million. Ekso Bionics had a negative return on equity of 169.75% and a negative net margin of 327.12%. equities research analysts anticipate that Ekso Bionics Holdings Inc will post -0.45 EPS for the current year.

About Ekso Bionics (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Read More: Price to Earnings Ratio (PE)

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.